

<b>Indication</b>	Peri-operative treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma. Suitable for fit patients only, with PS 0 - 1
<b>Treatment Intent</b>	Neo-adjuvant / adjuvant treatment
<b>Frequency and number of cycles</b>	Every 14 days for 4 cycles before surgery and 4 cycles after surgery
<b>Monitoring parameters pre-treatment</b>	<ul style="list-style-type: none"> <li>• Monitor FBC, U&amp;Es and LFT's at each cycle.</li> <li>• If neuts <math>\geq 1.5</math> and PLT <math>\geq 100</math> continue with treatment. If neuts 1.0-1.4 and Plts <math>\geq 100</math> d/w consultant. If neuts <math>&lt; 1.0</math> or Plts <math>&lt; 100</math> delay one week</li> <li>• Impaired renal and liver function d/w consultant. <ul style="list-style-type: none"> <li>○ Hepatic: Consider dose reduction of docetaxel in liver impairment. Docetaxel not recommended in severe hepatic impairment (serum bilirubin <math>&gt; \text{ULN}</math> and/or ALT/ AST <math>&gt; 3.5</math> times the ULN associated with alkaline phosphatase <math>&gt; 6</math> times the ULN). 5-Fluorouracil - consider reducing dose in moderate or severe hepatic impairment.</li> <li>○ Renal: If GFR is 30-50ml/min monitor renal function and consider dose reduction of oxaliplatin if toxicity. Omit oxaliplatin if CrCl <math>&lt; 30</math>ml/min.</li> </ul> </li> <li>• <b>Ensure dexamethasone pre-medication is prescribed and given to the patient at new patient chat</b></li> <li>• Reference should be made to 'Guidance on the Assessment and Management of Oxaliplatin Induced Neuropathy' available at: <a href="http://www.kentmedwaycancerguide.nhs.uk/medicines-and-prescribing-incorporating-sact-pathways/sact-pathways-guidelines-for-the-management-of-sact-induced-adverse-reactions-and-nursing/">http://www.kentmedwaycancerguide.nhs.uk/medicines-and-prescribing-incorporating-sact-pathways/sact-pathways-guidelines-for-the-management-of-sact-induced-adverse-reactions-and-nursing/</a></li> <li>• Dose reduction should be considered if any other grade 3 or 4 non-haematological toxicity or repeat appearance of grade 2 (except N&amp;V and alopecia). Delay until resolution of toxicity to <math>\leq</math> grade 1</li> </ul>
<b>Reference(s)</b>	Proceedings ASCO 2017; Abstract 4004 Al-Batran et al JCO 35(suppl)

NB For funding information, refer to the SACT funding spreadsheet

Protocol No	UGI-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.	
Version	1.0 FINAL	Written by	C Waters
Supersedes version	n/a	Checked by	E Parry
Date	26/9/17	Authorising consultant (usually NOG Chair)	T Sevitt / M Cominos

Day	Drug	Dose	Route	Infusion Duration	Administration Details		
<b>1</b>	Ondansetron	<75yrs 16mg ≥75yrs 8mg	iv	15 min	NaCl 0.9% 50ml		
	<b>DOCETAXEL</b>	<b>50mg/m<sup>2</sup></b>	IV	1 hr	Sodium Chloride 0.9% 250ml		
	<b>Flush with 5% glucose before and after oxaliplatin administration</b>						
	<b>OXALIPLATIN</b>	<b>85mg/m<sup>2</sup></b>	iv	2 - 6hrs	250-500ml 5% glucose (to give a concentration between 0.2 mg/ml and 0.70 mg/ml)	<b>Can be run concurrently</b>	
	<b>CALCIUM FOLINATE (calcium leucovorin)</b>	<b>200mg/m<sup>2</sup></b>	iv	2 hrs	Glucose 5% 250ml		
	<b>5-FLUOROURACIL</b>	<b>2600mg/m<sup>2</sup></b>	iv	<b>24 hr pump</b>	continuous infusion		
TTO	Drug	Dose	Route	Directions			
	Dexamethasone	8mg	po	bd for 3 days starting one day prior to next cycle of chemotherapy			
	Metoclopramide	10mg	po	3 times a day for 3 days, then 10mg up to 3 times a day as required. Do not take for more than 5 days continuously.			
	Filgrastim	300 micrograms or consider dose of 480 micrograms if patient > 80kg	sub cut	od starting on day 4 for 5 days			

Protocol No	UGI-058	Kent and Medway SACT Protocol Disclaimer: No responsibility will be accepted for the accuracy of this information when used elsewhere.		
Version	1.0 FINAL	Written by		C Waters
Supersedes version	n/a	Checked by		E Parry
Date	26/9/17	Authorising consultant (usually NOG Chair)		T Sevitt / M Cominos